Arnulf Stenzl

Active 1990–2025

178
Papers
23,147
Citations
85
h-index
165
i10-index

Citations

Citations per year for Arnulf Stenzl1991: 1 citations1992: 3 citations1994: 2 citations1995: 5 citations1996: 6 citations1997: 12 citations1998: 11 citations1999: 8 citations2000: 6 citations2001: 24 citations2002: 18 citations2003: 22 citations2004: 18 citations2005: 26 citations2006: 23 citations2007: 33 citations2008: 40 citations2009: 78 citations2010: 95 citations2011: 116 citations2012: 141 citations2013: 179 citations2014: 190 citations2015: 156 citations2016: 169 citations2017: 191 citations2018: 184 citations2019: 624 citations2020: 660 citations2021: 702 citations2022: 586 citations2023: 529 citations2024: 781 citations2025: 375 citations2026: 16 citations1993: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,942 citing papers, 19% of this breakdownChina: 965 citing papers, 9.4% of this breakdownGermany: 843 citing papers, 8.2% of this breakdownUnited Kingdom: 651 citing papers, 6.4% of this breakdownItaly: 639 citing papers, 6.2% of this breakdownFrance: 448 citing papers, 4.4% of this breakdownNetherlands: 423 citing papers, 4.1% of this breakdownCanada: 414 citing papers, 4.1% of this breakdownSpain: 332 citing papers, 3.2% of this breakdownJapan: 317 citing papers, 3.1% of this breakdownSwitzerland: 300 citing papers, 2.9% of this breakdownAustria: 263 citing papers, 2.6% of this breakdown
0%19%Other 26.4%

Fields

  • Medicine70.1%
  • Biochemistry, Genetics and Molecular Biology16.4%
  • Immunology and Microbiology8%
  • Engineering2.4%
  • Computer Science0.8%
  • Psychology0.6%
  • Other1.7%

Topics

  • Bladder and Urothelial Cancer Treatments9.6%
  • Prostate Cancer Treatment and Research7.1%
  • Prostate Cancer Diagnosis and Treatment6%
  • Urinary and Genital Oncology Studies5%
  • Immunotherapy and Immune Responses3.7%
  • Cancer Immunotherapy and Biomarkers3.4%
  • Other65.2%

Coauthors

All papers

Open in search
  1. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    Authors: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 1,186

  2. Current best practice for bladder cancer: a narrative review of diagnostics and treatments

    Authors: , , , , , , , , - The Lancet 2022 cited by 434

  3. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 299

  4. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 277

  5. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

    Authors: , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2015 cited by 284

  6. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions

    Authors: , , , - Urologic Oncology Seminars and Original Investigations 2020 cited by 215

  7. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease

    Authors: , , , , , , - European Urology 2014 cited by 571

  8. Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Celestia S. Higano, Matti Aapro, Michael Krainer, Stephan Hruby, Johannes Meran, S. Polyakov, Jean‐Pascal Machiels, Thierry Roumeguère, Koen Ackaert, Nicolaas Lumen, Thierry Gil, Velko Minchev, Antoaneta Tomova, Borislav D. Dimitrov, Marchela Koleva, Antonio Juretić, Ana Fröbe, Željko Vojnović, Martin Drabek, L. Jarolím, Tomáš Büchler, Eva Kindlová, Jan Schraml, Milada Zemanová, Prausova Jana, Bohuslav Melichar, Martina Chodacká, Jan Jansa, Gedske Daugaard, Nicolas Delonchamps, Brigitte Duclos, Stéphane Culine, G. Deplanque, Sylvestre Le Moulec, Peter Hammerer, Gerald Rodemer, Manuel Ritter, Axel S. Merseburger, Marc‐Oliver Grimm, Ilija Damjanoski, Manfred Wirth, Martin Burmester, Kurt Miller, Jan Herden, Bastian Keck, Christian Wuelfing, Alexander Winter, Martin Boegemann, Ingo Kausch von Schmeling, Paolo Fornara, E. Jaeger, G. Bodoky, Zsuzsanna Pápai, Géza Böszörményi-Nagy, Paola Vanella, Héctor Soto Parrà, Rodolfo Passalacqua, Francesco Ferraù, Michele Maio, Lucia Fratino, Enrico Cortesi, Gunta Purkalne, Jolita Asadauskienė, Rasa Jančiauskienė, Skaistė Tulytė, Alvydas Česas, Marco B. Polée, Brigitte C.M. Haberkorn, Fons van de Eertwegh, Pieter van den Berg and 83 more - JAMA Oncology 2022 cited by 90

  9. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021

    Authors: , , , , , , , - European Urology 2021 cited by 220

  10. Prevention and early detection of prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2014 cited by 492

  11. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kosei Hirakawa, Hiroaki Tanaka, Stefan Stevanović, Jürgen Frisch, Andrea Mayer-Mokler, Alexandra Kirner, Hans-Georg Rammensee, Carsten Reinhardt, Harpreet Singh‐Jasuja - Nature Medicine 2012 cited by 784

  12. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial

    Authors: , , , , , , , , , , , , , , , , , , , - European Urology 2018 cited by 337

  13. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 247

  14. Economic aspects of bladder cancer: what are the benefits and costs?

    Authors: , , , , , , , , - World Journal of Urology 2009 cited by 492

  15. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer

    Authors: , , , , , , , - Urologic Oncology Seminars and Original Investigations 2017 cited by 184

  16. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2017 cited by 164

  17. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer

    Authors: , , , - Human Vaccines & Immunotherapeutics 2014 cited by 114

  18. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 216

  19. TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 cited by 46

  20. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 387

  21. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature

    Authors: , , , , , , , , , - European Urology 2015 cited by 278

  22. Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients

    Authors: , , , , , , , , , , , , , , - Molecular Therapy 2010 cited by 219

  23. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , - European Urology Oncology 2022 cited by 40

  24. Photodynamic Diagnosis of Non–muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data

    Authors: , , , , , , , , , , , , , - European Urology 2013 cited by 450